Two Senior FDA Officials Resign || A Big Problem! | One Doctor's Take
What this video covers
Recorded in early September 2021 — days after the news broke — this is Prasad’s first reaction to the resignations of Marion Gruber and Philip Krause from the FDA’s vaccine office. The video is short (just over five minutes) and raw: Prasad reacts in near-real time to reporting that the two officials were leaving because of frustration with the Biden administration’s booster plans.
Prasad presents the departures as a serious institutional warning sign. Drawing on reporting at the time, he argues the officials were at odds with top vaccine official Peter Marks and frustrated that the White House had announced booster plans — including a proposed September 20 start date for most adults — while the FDA had only authorized boosters for the immunocompromised. He frames this as the administration jumping ahead of its own regulators.
The tone is urgent and alarmist by Prasad’s own later standards, but it established the core thesis he would return to for years: that the booster rollout was political theater imposed on a reluctant scientific bureaucracy. He closes by arguing that losing senior career scientists over a policy dispute damages public trust in the agency.
Key points
- Prasad reacts to the then-fresh news (August 31, 2021 reporting) that Gruber and Krause were resigning from the FDA’s Office of Vaccines Research and Review.
- He argues the resignations were driven by frustration with the White House announcing booster plans before FDA authorization, citing contemporary reporting.
- According to Prasad, the two officials were also at odds with FDA vaccine chief Peter Marks over the CDC’s role in what they saw as FDA decisions.
- Prasad frames the departures as a major institutional loss, calling the officials veteran scientists whose exit signals dysfunction.
- He argues the White House’s proposed September 20 booster start date put politics ahead of the regulatory process.
- The video sets up Prasad’s longer-running argument that broad booster recommendations were a political decision rather than an evidence-based one.